A 2020 vision for vaccines against HIV, tuberculosis and malaria. (Q47980915)

7 February 2018

title

A 2020 vision for vaccines against HIV, tuberculosis and malaria. (English)

1 reference

7 February 2018

0 references

1 reference

1 reference

1

Rino Rappuoli

1 reference

7 February 2018

Alan Aderem

2

1 reference

7 February 2018

language of work or name

English

0 references

publication date

1 May 2011

1 reference

7 February 2018

published in

Nature

1 reference

7 February 2018

volume

473

1 reference

7 February 2018

issue

7348

1 reference

7 February 2018

page(s)

463-469

1 reference

7 February 2018

https://scigraph.springernature.com/pub.10.1038/nature10124

exact match

0 references

cites work

Induction of immunity to human immunodeficiency virus type-1 by vaccination

1 reference

https://api.crossref.org/works/10.1038%2FNATURE10124

Systems biology of innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE10124

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE10124

Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE10124

An HIV vaccine--evolving concepts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE10124

The role of antibodies in HIV vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE10124

Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE10124

Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE10124

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE10124

Public health. A sound rationale needed for phase III HIV-1 vaccine trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE10124

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE10124

Genomic analysis reveals pre- and postchallenge differences in a rhesus macaque AIDS vaccine trial: insights into mechanisms of vaccine efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE10124

An Ad5-vectored HIV-1 vaccine elicits cell-mediated immunity but does not affect disease progression in HIV-1-infected male subjects: results from a randomized placebo-controlled trial (the Step study)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE10124

Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE10124

Induction of broadly neutralizing H1N1 influenza antibodies by vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE10124

Comparative genomics of BCG vaccines by whole-genome DNA microarray

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE10124

Advances in tuberculosis vaccine strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE10124

Future Vaccination Strategies against Tuberculosis: Thinking outside the Box

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE10124

A multistage tuberculosis vaccine that confers efficient protection before and after exposure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE10124

New vaccines for tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE10124

A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE10124

An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE10124

Protective Immunity produced by the Injection of X-irradiated Sporozoites of Plasmodium berghei

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE10124

Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE10124

Progress and challenges for malaria vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE10124

Immunity to malaria: more questions than answers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE10124

Does malaria suffer from lack of memory?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE10124

Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE10124

GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE10124

A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE10124

Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE10124

Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE10124

Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE10124

Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE10124

Malaria vaccine design: immunological considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE10124

Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE10124

Structural basis of antigenic escape of a malaria vaccine candidate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE10124

Humoral immune response to mixed PfAMA1 alleles; multivalent PfAMA1 vaccines induce broad specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE10124

A diversity-covering approach to immunization with Plasmodium falciparum apical membrane antigen 1 induces broader allelic recognition and growth inhibition responses in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE10124

Experimental human challenge infections can accelerate clinical malaria vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE10124

The quest for a T cell-based immune correlate of protection against HIV: a story of trials and errors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE10124

HIV-1 vaccines and adaptive trial designs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE10124

Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE10124

Meningococcal C conjugate vaccine: the experience in England and Wales

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE10124

21 January 2018

The value of vaccines

1 reference

https://api.crossref.org/works/10.1038%2FNATURE10124

Rational design of a meningococcal antigen inducing broad protective immunity

21 January 2018

1 reference

12 December 2020

Delivering a safe and effective strain-specific vaccine to control an epidemic of group B meningococcal disease

1 reference

12 December 2020

Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients

1 reference

12 December 2020

Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans

1 reference

12 December 2020

Structure-based antigen design: a strategy for next generation vaccines

1 reference

12 December 2020

Human gene expression profiles of susceptibility and resistance in tuberculosis.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NATURE10124

1 reference

7 February 2018

Dimensions Publication ID

0 references

1 reference

7 February 2018